Arikayce Suspension
Product Images NDC 71558-590

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Arikayce (NDC 71558-590). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Insmed Incorporated, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Arikayce 01)

FDA Label Image

Image (Arikayce 02)

Image (Arikayce 02)
This appears to be a chart showing the percentage of subjects achieving "culture conversion" in a clinical trial, for two different drug regimens, over a period of five months. The first drug regimen (V-230) achieved a cumulative proportion of 29% of subjects achieving culture conversion by the end of the first month, while the second drug regimen (V-113) achieved a cumulative proportion of 27.2% by the end of the same period. The chart then shows the cumulative proportion of converters over the following four months.*
FDA Label Image

Figure (Arikayce 03)

FDA Label Image

Figure (Arikayce 04)

FDA Label Image

Figure (Arikayce 05)

FDA Label Image

Figure (Arikayce 06)

FDA Label Image

Figure (Arikayce 07)

FDA Label Image

Figure (Arikayce 08)

FDA Label Image

Figure (Arikayce 09)

FDA Label Image

Figure (Arikayce 10)

FDA Label Image

Figure (Arikayce 11)

FDA Label Image

Figure (Arikayce 12)

FDA Label Image

Figure (Arikayce 13)

FDA Label Image

Figure (Arikayce 14)

FDA Label Image

Figure (Arikayce 15)

FDA Label Image

Arikayce 15a

FDA Label Image

Figure (Arikayce 16)

FDA Label Image

Figure (Arikayce 17)

FDA Label Image

Figure (Arikayce 18)

FDA Label Image

Figure (Arikayce 19)

FDA Label Image

Figure (Arikayce 20)

FDA Label Image

Figure (Arikayce 21)

FDA Label Image

Figure (Arikayce 22)

FDA Label Image

Figure (Arikayce 23)

FDA Label Image

Figure (Arikayce 24)

FDA Label Image

Figure (Arikayce 25)

FDA Label Image

Figure (Arikayce 26)

FDA Label Image

Principal Display Panel (8.4 mL Vial Carton)

Principal Display Panel (8.4 mL Vial Carton)
ARIKAYCE is a medication designed for oral inhalation only. It contains 28 sterile unit-dose vials, each containing amikacin 590mg/8.4mL (equivalent to amikacin sulfate 623mg/8.4mL). The medication is for a limited population only. Patients who want to use this medication are advised to store it refrigerated until the expiration date on the vial. Once expired, any unused medicine should be discarded. The medication can also be stored at room temperature up to 4 weeks. ARIKAYCE should be used with the Lamira Nebulizer Handset and Lamira Asrosol Heads provided. If interested, the full prescribing information for ARIKAYCE can be accessed. The product is manufactured for Insmed Incorporated, located in Bridgewater, NJ.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.